Evidence map›Paper›PMID 42644027›Full record

ArticleCase reports in urology2026

Adenocarcinoma of the Rete Testis With PI3K/AKT/mTOR Pathway Alteration and a Gene Expression Profile Resembling Papillary Renal Cell Carcinoma: A Case Report.

Sachein Sharma, Ryan Jaehne, Cyrus Oster, Dong Ren, Shivani Kandukuri, Li Lei, Dimitrios Korentzelos, Matthew J Oberley, Eugene Muchnik, Mark G Evans

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sachein SharmaCaris Life Sciences, Phoenix, Arizona, USA, carislifesciences.com.ORCID https://orcid.org/0009-0006-6302-2882
Ryan JaehneCaris Life Sciences, Phoenix, Arizona, USA, carislifesciences.com.ORCID https://orcid.org/0009-0004-4135-2325
Cyrus OsterCaris Life Sciences, Phoenix, Arizona, USA, carislifesciences.com.
Dong RenPathology and Laboratory Medicine, UC Irvine School of Medicine, Irvine, California, USA, uci.edu.ORCID https://orcid.org/0000-0002-0843-0246
Shivani KandukuriPathology and Laboratory Medicine, UC Irvine School of Medicine, Irvine, California, USA, uci.edu.
Li LeiPathology, UC San Diego School of Medicine, La Jolla, California, USA, ucsd.edu.ORCID https://orcid.org/0000-0001-6872-3094
Dimitrios KorentzelosPathology, UPMC Shadyside, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0099-7499
Matthew J OberleyCaris Life Sciences, Phoenix, Arizona, USA, carislifesciences.com.
Eugene MuchnikHematology/Oncology, UPMC Susquehanna, Williamsport, Pennsylvania, USA.
Mark G EvansCaris Life Sciences, Phoenix, Arizona, USA, carislifesciences.com.ORCID https://orcid.org/0000-0001-9358-9843

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenocarcinoma of the rete testis (ACRT) is a rare, gland-forming neoplasm arising from rete testis epithelium and is typically associated with poor prognosis. Currently, our knowledge of ACRT has been limited to single reports and small series, and its molecular characteristics are largely unknown. We present a patient, whose scrotal tumor demonstrated a gene expression profile similar to that of papillary renal cell carcinoma (PRCC) and alteration of PI3K/AKT/mTOR pathway, thereby expanding our understanding of the genomic landscape of ACRT.

Indexed as

adenocarcinoma of the rete testiscase reportgenitourinary tumorsnext-generation sequencingpapillary renal cell carcinomaPI3K/AKT/mTOR pathway

Identifiers

PMID42644027
PMCPMC13504671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.